Pre-Open Stock Movers 11/21: (GMCR) (WSM) (HOLX) Higher; (SGOC) (BV) (LQDT) Lower (more...)

November 21, 2013 9:35 AM EST
SGOCO Group, Ltd (NASDAQ: SGOC) 12.4% LOWER; sees a 'sell the news' after earnings

Bazaarvoice (NASDAQ: BV) 12.4% LOWER; reported Q2 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $45.5 million versus the consensus estimate of $44.95 million. Also, Stephen Collins will step down as CEO and as a member of the Board of Directors.

Green Mountain Coffee Roasters (NASDAQ: GMCR) 11.9% HIGHER; reported Q4 EPS of $0.89, $0.14 better than the analyst estimate of $0.75. Revenue for the quarter came in at $1 million versus the consensus estimate of $966.27 million. Green Mountain Coffee Roasters sees Q1 2014 EPS of $0.85-$0.90, versus the consensus of $0.96. Green Mountain Coffee Roasters sees FY2014 EPS of $3.75-$3.85, versus the consensus of $3.78. Separately today, the Company announced its Board of Directors has approved a new share repurchase authorization of up to $1 billion. The new share repurchase program will take effect upon completion of the Company’s current program, which has $138 million remaining of its previously authorized $500 million. The Company also announced the Board approved an indicated annual dividend of $1.00 per share, payable $0.25 per quarter and declared a quarterly cash dividend of $0.25 per share. Upgraded at Janney

Liquidity Services, Inc. (NASDAQ: LQDT) 9.2% LOWER; reported Q4 EPS of $0.41, $0.04 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $129.1 million versus the consensus estimate of $124.5 million.

Valuevision Media, Inc. (NASDAQ: VVTV) 8.6% LOWER; reported Q3 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $147 million versus the consensus estimate of $150.41 million.

InterCloud Systems, Inc. (Nasdaq: ICLD) 7.7% HIGHER; rannounced today that its Professional Services Group was recently awarded over $2.5 million in new professional services contracts, from new and existing clients.

Attunity Ltd. (NASDAQ: ATTU) 6.7% LOWER; commenced a public offering of its ordinary shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Attunity intends to use the net proceeds from the sale of the ordinary shares in connection with its strategic plan, including for expanding its sales, marketing and research and development activities, as well as acquisitions and investments, and for working capital and other general corporate purposes.

Williams-Sonoma, Inc. (NYSE: WSM) 5.8% HIGHER; reported Q3 EPS of $0.58, $0.03 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.04 billion. Williams-Sonoma, Inc. sees Q4 2013 EPS of $1.30-$1.37, versus the consensus of $1.36. Williams-Sonoma, Inc. sees Q4 2013 revenue of $1.37-1.43 million, versus the consensus of $1.43 million. Comparable brand revenue growth in Q4 13 is expected to be in the range of 3% to 6%.

Dollar Tree, Inc. (NASDAQ: DLTR) 5.5% LOWER; reported Q3 EPS of $0.58, $0.02 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $1.88 billion versus the consensus estimate of $1.91 billion. Dollar Tree, Inc. sees Q4 2013 EPS of $1.01-$1.07, versus the consensus of $1.10. Dollar Tree, Inc. sees Q4 2013 revenue of $2.25-2.31 billion, versus the consensus of $2.32 billion. Dollar Tree, Inc. sees FY2013 EPS of $2.72-$2.78, versus the consensus of $2.82. Dollar Tree, Inc. sees FY2013 revenue of $7.86-7.92 billion, versus the consensus of $7.95 billion.

WebMD Health Corp. (Nasdaq: WBMD) 4.7% LOWER; announced that it intends to offer $300 million of Convertible Notes due 2020 in a private placement. WebMD also expects to grant the initial purchaser in the proposed offering an option to purchase up to an additional $50 million aggregate principal amount of notes. The notes are being offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.

Aeropostale, Inc. (NYSE: ARO) 4.8% HIGHER; Crescendo Partners sent a letter to the board of Aeropostale urging the company immediately purse a sale.

Oncolytics Biotech Inc. (NASDAQ: ONCY) 4.4% HIGHER; announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-na ve head and neck cancers (REO 018).

Target Corp. (NYSE: TGT) 4.7% LOWER; results and outlook

Jack in the Box, Inc. (Nasdaq: JACK) 3.5% HIGHER; reported Q4 EPS of $0.45, $0.06 better than the analyst estimate of $0.39. Revenue for the quarter came in at $0 versus the consensus estimate of $336.28 million. Jack in the Box comps down 1.4 percent, Qdoba comps up 2.0 percent. Sees FY2014 EPS of $2.15-$2.30, versus the consensus of $2.17. Same-store sales are expected to increase approximately 1.5 to 2.5 percent at Jack in the Box company restaurants. Same-store sales are expected to increase approximately 2.0 to 3.0 percent at Qdoba company restaurants.

Limited Brands, Inc. (NYSE: LTD) 3.4% LOWER; reported Q3 EPS of $0.31, $0.03 better than the analyst estimate of $0.28. Revenue for the quarter came in at $2.17 billion versus the consensus estimate of $2.17 billion. Limited Brands, Inc. sees Q4 2013 EPS of $1.67-$1.82, versus the consensus of $1.83. For 2013, the company expects earnings per share of $3.07 to $3.22. The fourth quarter projection includes incremental interest expense of approximately $0.02 per share related to the $500 million notes issued in October, which was not included in the company's previous forecast.

Hologic Inc. (NASDAQ: HOLX) 2% HIGHER; Carl Icann just filed his 13D and showed a 34,154,879 share, or 12.63% stake in the company. The company adopted a poison pill.

Amicus Therapeutics, Inc. (Nasdaq: FOLD) 2% HIGHER; Amicus and GlaxoSmithKline (NYSE: GSK) today announced that Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Acquires Callidus Biopharma.

Tower Group International, Ltd. (NASDAQ: TWGP) 2% LOWER; receives NASDAQ delisting notice

Philip Morris International (NYSE: PM) 2% LOWER; Goldman Sachs downgraded from Conviction Buy to Neutral with and cut their price target from $103 to $95.

Rite-Aid (NYSE: RAD) 1% HIGHER; Deutsche Bank initiated coverage with a Buy rating and price target of $7.00.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Deutsche Bank, Crescendo Partners, Dividend, 13D, Stock Buyback, Earnings